Alessio Squassina

List of Publications by Year
in descending order

123 papers	6,921 citations	168829 31 h-index	87275 74 g-index
145 all docs	145 docs citations	145 times ranked	10807 citing authors

#	Article	IF	Citations
1	Recommendations for pharmacotranscriptomic profiling of drug response in CNS disorders. European Neuropsychopharmacology, 2022, 54, 41-53.	0.3	4
2	Transcriptional biomarkers of response to pharmacological treatments in severe mental disorders: A systematic review. European Neuropsychopharmacology, 2022, 55, 112-157.	0.3	7
3	Genetic and Epigenetic Markers of Lithium Response. International Journal of Molecular Sciences, 2022, 23, 1555.	1.8	6
4	A bidirectional competitive interaction between circHomer1 and Homer1b within the orbitofrontal cortex regulates reversal learning. Cell Reports, 2022, 38, 110282.	2.9	17
5	Pharmacogenomics and mood stabilizers: efficacy and adverse drug reactions. , 2022, , 203-222.		0
6	Using polygenic scores and clinical data for bipolar disorder patient stratification and lithium response prediction: machine learning approach. British Journal of Psychiatry, 2022, 220, 219-228.	1.7	11
7	Gut microbiota and treatment-resistant schizophrenia: many questions, fewer answers. Pharmacogenomics, 2022, 23, 277-280.	0.6	1
8	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
9	Is Poor Lithium Response in Individuals with Bipolar Disorder Associated with Increased Degradation of Tryptophan along the Kynurenine Pathway? Results of an Exploratory Study. Journal of Clinical Medicine, 2022, 11, 2517.	1.0	6
10	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	4.5	31
11	Association of polygenic score for major depression with response to lithium in patients with bipolar disorder. Molecular Psychiatry, 2021, 26, 2457-2470.	4.1	44
12	Exemplar scoring identifies genetically separable phenotypes of lithium responsive bipolar disorder. Translational Psychiatry, 2021, 11, 36.	2.4	16
13	Prediction of lithium response using genomic data. Scientific Reports, 2021, 11, 1155.	1.6	11
14	Presenting Psychiatric and Neurological Symptoms and Signs of Brain Tumors before Diagnosis: A Systematic Review. Brain Sciences, 2021, 11, 301.	1.1	9
15	Investigation of genetic loci shared between bipolar disorder and risk-taking propensity: potential implications for pharmacological interventions. Neuropsychopharmacology, 2021, 46, 1680-1692.	2.8	2
16	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
17	Protocol for a pharmacogenetic study of antidepressants. Psychiatric Genetics, 2021, Publish Ahead of Print, 186-193.	0.6	1
18	Involvement of Gut Microbiota in Schizophrenia and Treatment Resistance to Antipsychotics. Biomedicines, 2021, 9, 875.	1.4	21

#	Article	IF	Citations
19	Personalized treatments in neuropsychiatric disorders. Drug Development Research, 2021, 82, 618-620.	1.4	0
20	Characterisation of age and polarity at onset in bipolar disorder. British Journal of Psychiatry, 2021, 219, 659-669.	1.7	20
21	HLA-DRB1 and HLA-DQB1 genetic diversity modulates response to lithium in bipolar affective disorders. Scientific Reports, 2021, 11, 17823.	1.6	10
22	W68. A META-ANALYSIS OF POLYGENIC RISK SCORES FOR MOOD DISORDERS, NEUROTICISM, AND SCHIZOPHRENIA IN ANTIDEPRESSANT RESPONSE. European Neuropsychopharmacology, 2021, 51, e180.	0.3	0
23	Pharmacogenomics of bipolar disorder. , 2021, , 135-142.		0
24	Investigating the Role of Leukocyte Telomere Length in Treatment-Resistant Depression and in Response to Electroconvulsive Therapy. Journal of Personalized Medicine, 2021, 11, 1100.	1.1	3
25	Association of Attention-Deficit/Hyperactivity Disorder and Depression Polygenic Scores with Lithium Response: A Consortium for Lithium Genetics Study. Complex Psychiatry, 2021, 7, 80-89.	1.3	6
26	Combining schizophrenia and depression polygenic risk scores improves the genetic prediction of lithium response in bipolar disorder patients. Translational Psychiatry, 2021, 11, 606.	2.4	25
27	Circular RNA circCCNT2 is upregulated in the anterior cingulate cortex of individuals with bipolar disorder. Translational Psychiatry, 2021, 11, 629.	2.4	3
28	P.0882 A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. European Neuropsychopharmacology, 2021, 53, S646-S647.	0.3	0
29	Leukocyte telomere length is reduced in patients with major depressive disorder. Drug Development Research, 2020, 81, 268-273.	1.4	13
30	Major depression subtypes are differentially associated with migraine subtype, prevalence and severity. Cephalalgia, 2020, 40, 347-356.	1.8	12
31	An examination of the quality and performance of the Alda scale for classifying lithium response phenotypes. Bipolar Disorders, 2020, 22, 255-265.	1.1	24
32	Pharmacogenomics of bipolar disorder. , 2020, , 393-402.		2
33	Increasing engagement in pharmacology and pharmacogenetics education using games and online resources: The PharmacoloGenius mobile app. Drug Development Research, 2020, 81, 985-993.	1.4	1
34	P.266 Analysis of gut microbiota composition in patients with major depressive disorder characterized as treatment resistant or responders to antidepressants. European Neuropsychopharmacology, 2020, 40, S152.	0.3	0
35	P.353 Peripheral melatonin levels in bipolar disorder: preliminary results of a cross-sectional analysis. European Neuropsychopharmacology, 2020, 40, S205-S206.	0.3	0
36	Telomere attrition and inflammatory load in severe psychiatric disorders and in response to psychotropic medications. Neuropsychopharmacology, 2020, 45, 2229-2238.	2.8	21

#	Article	IF	Citations
37	Exploring the Role of Gut Microbiota in Major Depressive Disorder and in Treatment Resistance to Antidepressants. Biomedicines, 2020, 8, 311.	1.4	34
38	Challenges and Future Prospects of Precision Medicine in Psychiatry . Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 127-140.	0.4	42
39	Differences in telomere length between patients with bipolar disorder and controls are influenced by lithium treatment. Pharmacogenomics, 2020, 21, 533-540.	0.6	26
40	Application of Support Vector Machine on fMRI Data as Biomarkers in Schizophrenia Diagnosis: A Systematic Review. Frontiers in Psychiatry, 2020, 11, 588.	1.3	71
41	Clinical, genetic, and brain imaging predictors of risk for bipolar disorder in high-risk individuals. Expert Review of Molecular Diagnostics, 2020, 20, 327-333.	1.5	7
42	A multidisciplinary approach to mental illness: do inflammation, telomere length and microbiota form a loop? A protocol for a cross-sectional study on the complex relationship between inflammation, telomere length, gut microbiota and psychiatric disorders. BMJ Open, 2020, 10, e032513.	0.8	10
43	MicroRNA expression profiling of lymphoblasts from bipolar disorder patients who died by suicide, pathway analysis and integration with postmortem brain findings. European Neuropsychopharmacology, 2020, 34, 39-49.	0.3	15
44	Investigating polygenic burden in age at disease onset in bipolar disorder: Findings from an international multicentric study. Bipolar Disorders, 2019, 21, 68-75.	1.1	20
45	Clinical and genetic determinants of serum brain-derived neurotrophic factor (BDNF) levels in psychotic patients: A longitudinal prospective study. European Neuropsychopharmacology, 2019, 29, S133-S134.	0.3	0
46	SU98CONVERGENT ANALYSIS OF SEQUENCING AND MICROARRAY DATA SUGGEST THE INVOLVEMENT OF MIRNAS AND THEIR TARGET MRNAS IN RESPONSE TO LITHIUM TREATMENT IN BIPOLAR DISORDER. European Neuropsychopharmacology, 2019, 29, S1317-S1318.	0.3	0
47	Mood Disorders, Accelerated Aging, and Inflammation: Is the Link Hidden in Telomeres?. Cells, 2019, 8, 52.	1.8	38
48	Treatment-Resistant Schizophrenia: Insights From Genetic Studies and Machine Learning Approaches. Frontiers in Pharmacology, 2019, 10, 617.	1.6	19
49	Lithium pharmacogenetics. Psychiatry Research, 2019, 279, 401.	1.7	1
50	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
51	P.049 The impact of depot and long acting injectable antipsychotics on BDNF serum levels in psychosis: a 24-month longitudinal prospective study. European Neuropsychopharmacology, 2019, 29, S54-S55.	0.3	0
52	Evidence that genes involved in hedgehog signaling are associated with both bipolar disorder and high BMI. Translational Psychiatry, 2019, 9, 315.	2.4	19
53	Zinc finger proteins in psychiatric disorders and response to psychotropic medications. Psychiatric Genetics, 2019, 29, 132-141.	0.6	13
54	Whole Genome Expression Analyses of miRNAs and mRNAs Suggest the Involvement of miR-320a and miR-155-3p and their Targeted Genes in Lithium Response in Bipolar Disorder. International Journal of Molecular Sciences, 2019, 20, 6040.	1.8	28

#	Article	IF	Citations
55	RNA sequencing of bipolar disorder lymphoblastoid cell lines implicates the neurotrophic factor HRP-3 in lithiumâ€™s clinical efficacy. World Journal of Biological Psychiatry, 2019, 20, 449-461.	1.3	13
56	Investigating the relationship between melatonin levels, melatonin system, microbiota composition and bipolar disorder psychopathology across the different phases of the disease. International Journal of Bipolar Disorders, 2019, 7, 27.	0.8	11
57	Association of Polygenic Score for Schizophrenia and HLA Antigen and Inflammation Genes With Response to Lithium in Bipolar Affective Disorder. JAMA Psychiatry, 2018, 75, 65-74.	6.0	102
58	Recent trends on the role of epigenomics, metabolomics and noncoding RNAs in rationalizing mood stabilizing treatment. Pharmacogenomics, 2018, 19, 129-143.	0.6	10
59	Understanding the molecular mechanisms underlying mood stabilizer treatments in bipolar disorder: Potential involvement of epigenetics. Neuroscience Letters, 2018, 669, 24-31.	1.0	32
60	Involvement of core clock genes in lithium response. World Journal of Biological Psychiatry, 2018, 19, 645-646.	1.3	8
61	Genetically elevated highâ€density lipoprotein cholesterol through the cholesteryl ester transfer protein gene does not associate with risk of Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 595-598.	1.2	2
62	Convergent analysis of genomeâ€wide genotyping and transcriptomic data suggests association of zinc finger genes with lithium response in bipolar disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 658-664.	1.1	10
63	The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine. Molecular Diagnosis and Therapy, 2018, 22, 409-420.	1.6	35
64	SIRT1, miR-132 and miR-212 link human longevity to Alzheimerâ€™s Disease. Scientific Reports, 2018, 8, 8465.	1.6	89
65	The Genomic Medicine Alliance: A Global Effort to Facilitate the Introduction of Genomics into Healthcare in Developing Nations. , 2018, , 173-188.		1
66	Analysis of the Influence of microRNAs in Lithium Response in Bipolar Disorder. Frontiers in Psychiatry, 2018, 9, 207.	1.3	28
67	We are not Alone in Our Body: Insights into the Involvement of Microbiota in the Etiopathogenesis and Pharmacology of Mental Illness. Current Drug Metabolism, 2018, 19, 688-694.	0.7	10
68	Telomere length in bipolar disorder and lithium response. European Neuropsychopharmacology, 2017, 27, 560-567.	0.3	30
69	557. Pharmacogenetic Association of Lithium Treatment Response with Bcl2 Polymorphism in Bipolar Disorder. Biological Psychiatry, 2017, 81, S225.	0.7	0
70	Evidence towards RNA Binding Motif (RNP1, RRM) Protein 3 (RBM3) as a Potential Biomarker of Lithium Response in Bipolar Disorder Patients. Journal of Molecular Neuroscience, 2017, 62, 304-308.	1.1	20
71	Pharmacogenetics of lithium effects on glomerular function in bipolar disorder patients under chronic lithium treatment: a pilot study. Neuroscience Letters, 2017, 638, 1-4.	1.0	13
72	Exploring Lithium Impact on Glomerular Function in Bipolar Patients Through Pharmacogenomics. European Psychiatry, 2017, 41, S102-S103.	0.1	0

#	Article	IF	Citations
73	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
74	A genetic risk score is differentially associated with migraine with and without aura. Human Genetics, 2017, 136, 999-1008.	1.8	22
75	Pharmacogenomics in Clinical Care andÂDrug Discovery. , 2017, , 281-303.		0
76	A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. PLoS ONE, 2016, 11, e0162866.	1.1	96
77	Test Pricing and Reimbursement in Genomic Medicine: Towards a General Strategy. Public Health Genomics, 2016, 19, 352-363.	0.6	37
78	Leukocyte telomere length positively correlates with duration of lithium treatment in bipolar disorder patients. European Neuropsychopharmacology, 2016, 26, 1241-1247.	0.3	59
79	RGS2 expression predicts amyloid-Î² sensitivity, MCI and Alzheimerâ€™s disease: genome-wide transcriptomic profiling and bioinformatics data mining. Translational Psychiatry, 2016, 6, e909-e909.	2.4	23
80	Minimum information required for a DMET experiment reporting. Pharmacogenomics, 2016, 17, 1533-1545.	0.6	6
81	Lithium Pharmacogenetics: Where Do We Stand?. Drug Development Research, 2016, 77, 368-373.	1.4	35
82	Genome-wide association study of 40,000 individuals identifies two novel loci associated with bipolar disorder. Human Molecular Genetics, 2016, 25, 3383-3394.	1.4	182
83	Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet, The, 2016, 387, 1085-1093.	6.3	306
84	HDAC3 role in medication consumption in medication overuse headache patients: a pilot study. Human Genomics, 2015, 9, 30.	1.4	7
85	Cellular models to study bipolar disorder: A systematic review. Journal of Affective Disorders, 2015, 184, 36-50.	2.0	49
86	Insulin-like Growth Factor 1 Differentially Affects Lithium Sensitivity of Lymphoblastoid Cell Lines from Lithium Responder and Non-responder Bipolar Disorder Patients. Journal of Molecular Neuroscience, 2015, 56, 681-687.	1.1	35
87	Preliminary Transcriptome Analysis in Lymphoblasts from Cluster Headache and Bipolar Disorder Patients Implicates Dysregulation of Circadian and Serotonergic Genes. Journal of Molecular Neuroscience, 2015, 56, 688-695.	1.1	38
88	Novel integrative genomic tool for interrogating lithium response in bipolar disorder. Translational Psychiatry, 2015, 5, e504-e504.	2.4	50
89	Investigation of the genetic interaction between BDNF and DRD3 genes in suicidal behaviour in psychiatric disorders. World Journal of Biological Psychiatry, 2015, 16, 171-179.	1.3	14
90	An Introduction to Pharmacogenomics and Personalized Medicine. , 2015, , 1053-1065.		1

#	Article	IF	Citations
91	Lithium-induced differential expression of SAT1 in suicide completers and controls is not correlated with polymorphisms in the promoter region of the gene. Psychiatry Research, 2014, 220, 1167-1168.	1.7	1
92	Assessment of the Pharmacogenomics Educational Environment in Southeast Europe. Public Health Genomics, 2014, 17, 272-279.	0.6	40
93	Bridging genomics research between developed and developing countries: the Genomic Medicine Alliance. Personalized Medicine, 2014, 11, 615-623.	0.8	22
94	Individualizing clozapine and risperidone treatment for schizophrenia patients. Pharmacogenomics, 2014, 15, 95-110.	0.6	6
95	C9<scp>ORF</scp>72 repeat expansion and bipolar disorder â€“ is there a link? No mutation detected in a Sardinian cohort of patients with bipolar disorder. Bipolar Disorders, 2014, 16, 667-668.	1.1	11
96	Pharmacogenomics and Personalized Medicine: Bridging Genetic Knowledge and Clinical Practice. , 2014, , 1-16.		0
97	Insulin-like growth factor 1 (IGF-1) expression is up-regulated in lymphoblastoid cell lines of lithium responsive bipolar disorder patients. Pharmacological Research, 2013, 73, 1-7.	3.1	66
98	No association of endocannabinoid genes with bipolar disorder or lithium response in a Sardinian sample. Psychiatry Research, 2013, 210, 887-890.	1.7	12
99	Investigation of endocannabinoid system genes suggests association between peroxisome proliferator activator receptor-Î± gene (PPARA) and schizophrenia. European Neuropsychopharmacology, 2013, 23, 749-759.	0.3	26
100	Pharmacogenomics of bipolar disorder. Pharmacogenomics, 2013, 14, 655-674.	0.6	28
101	Differential effect of lithium on spermidine/spermine N1-acetyltransferase expression in suicidal behaviour. International Journal of Neuropsychopharmacology, 2013, 16, 2209-2218.	1.0	21
102	Personalized medicine in bipolar disorder: how can we overcome the barriers to clinical translation?. Personalized Medicine, 2013, 10, 765-768.	0.8	5
103	Assessment of Response to Lithium Maintenance Treatment in Bipolar Disorder: A Consortium on Lithium Genetics (ConLiGen) Report. PLoS ONE, 2013, 8, e65636.	1.1	156
104	Conference Scene: Golden Helix Pharmacogenomics Days: educational activities on pharmacogenomics and personalized medicine. Pharmacogenomics, 2012, 13, 525-528.	0.6	7
105	Evidence for association of an ACCN1 gene variant with response to lithium treatment in Sardinian patients with bipolar disorder. Pharmacogenomics, 2011, 12, 1559-1569.	0.6	82
106	Age at onset in bipolar disorder: Investigation of the role of TaqIA polymorphism of DRD2 gene in a Sardinian sample. European Psychiatry, 2011, 26, 141-143.	0.1	13
107	The International Consortium on Lithium Genetics (ConLiGen): An Initiative by the NIMH and IGSLI to Study the Genetic Basis of Response to Lithium Treatment. Neuropsychobiology, 2010, 62, 72-78.	0.9	134
108	Pharmacogenomics of Mood Stabilizers in the Treatment of Bipolar Disorder. Human Genomics and Proteomics, 2010, 2, 159761.	1.5	19

#	Article	IF	Citations
109	Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics, 2010, 11, 1149-1167.	0.6	129
110	Association study of BDNF and DRD3 genes in schizophrenia diagnosis using matched caseâ€“control and family based study designs. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1412-1418.	2.5	18
111	NRG1 and BDNF genes in schizophrenia: An association study in an Italian case-control sample. Psychiatry Research, 2010, 176, 82-84.	1.7	24
112	Mixture regression analysis on age at onset in Bipolar Disorder patients: Investigation of the role of serotonergic genes. European Neuropsychopharmacology, 2010, 20, 663-670.	0.3	15
113	Migraine and tumour necrosis factor gene polymorphism. Journal of Neurology, 2009, 256, 194-197.	1.8	27
114	The diacylglycerol kinase eta gene and bipolar disorder: a replication study in a Sardinian sample. Molecular Psychiatry, 2009, 14, 350-351.	4.1	36
115	Association study in a Sardinian sample between bipolar disorder and the nuclear receptor REVâ€ERBÎ± gene, a critical component of the circadian clock system. Bipolar Disorders, 2009, 11, 215-220.	1.1	66
116	No association between lithium full responders and the DRD1, DRD2, DRD3, DAT1, 5-HTTLPR and HTR2A genes in a Sardinian sample. Psychiatry Research, 2009, 169, 164-166.	1.7	25
117	Interacting genes in lithium prophylaxis: Preliminary results of an exploratory analysis on the role of DGKH and NR1D1 gene polymorphisms in 199 Sardinian bipolar patients. Neuroscience Letters, 2009, 467, 67-71.	1.0	41
118	Association study of brainâ€derived neurotrophic factor (BDNF) and LINâ€7 homolog (LINâ€7) genes with adult attentionâ€deficit/hyperactivity disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 945-951.	1.1	45
119	The PDLIM5 gene and lithium prophylaxis: An association and gene expression analysis in Sardinian patients with bipolar disorder. Pharmacological Research, 2008, 57, 369-373.	3.1	27
120	Investigation of the dopamine D5 receptor gene (DRD5) in adult attention deficit hyperactivity disorder. Neuroscience Letters, 2008, 432, 50-53.	1.0	15
121	A caseâ€“control association study of the PDLIM5 gene and bipolar disorder in a Sardinian sample. Psychiatric Genetics, 2008, 18, 128-132.	0.6	6
122	Alzheimer's disease: Caseâ€control association study of polymorphisms in ACHE, CHAT, and BCHE genes in a Sardinian sample. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 895-899.	1.1	24
123	Linkage of M5 Muscarinic and Î±7-Nicotinic Receptor Genes on 15q13 to Schizophrenia. Neuropsychobiology, 2004, 50, 124-127.	0.9	62